Abstract-The aim of this study was to clarify the association between the inosine triphosphate pyrophos phatase (ITPA) gene variants and PEG IFNα/RBV combination treatment induced anemia in chronic hep atitis C (CHC) Ukrainian patients. The data were collected from 80 CHC patients with HCV genotype 1 infection. All study participants received standard doses of PEG IFNα and RBV. According to the Hb level changes patients were distributed into: case group-42 patients with combination treatment induced anemia, and control group-38 patients with no signs of anemia. Genotyping for ITPA gene rs1127354 and rs7270101 variants was performed using PCR followed by RFLP assay. Fisher's exact test was used to estimate the dif ference in genotype and allelic distribution. Distribution of rs7270101 genotypes was not significantly differ ent between groups of CHC patients with RBV induced anemia and without it. The frequency of rs1127354 A allele carriers was significantly higher (P < 0.05) in group of CHC patients without anemia (23.7%) com paring to the group of patients with anemia (7.3%). The respective allele frequency in control group (13.2%) was almost 3 fold higher (P < 0.05) comparing to the case group (4.9%). Significant association of ITPA gene rs1127354 with protection against RBV induced hemolytic anemia was found in Ukrainian patients with CHC infection. Rs1127354 variant may assist as a pharmacogenetic marker in HCV antiviral therapy correc tion for side effect avoidance.
INTRODUCTION
An estimated number of 150 million people is cur rently affected by hepatitis C virus (HCV) infection, which corresponds to 2.35% of the world population [1] . In 70-80% cases a primary HCV infection devel ops into chronic infection with its complications of liver cirrhosis and/or hepatocellular carcinoma [2] . Current approach to chronic hepatitis C (CHC) anti viral treatment includes pegylated interferon alfa (PEG IFN) and ribavirin (RBV) combination therapy [3] . However, despite its advances in the treatment of CHC, combination therapy is also associated with var ious toxic effects like psychiatric illness, constitutional side effects, and cytopenias [4] . The most common side effect of RBV treatment is hemolytic anemia which is also the major cause for RBV dose reduction [5] . Studies report that those patients receiving less than 60% of the initially selected RBV dose have a 1 The article is published in the original.
lower response rate and a higher relapse rate compar ing to patients receiving a higher dose [6] .
In recent years, genome wide association studies (GWASs) have demonstrated a strong association between single nucleotide polymorphisms (SNP) of the inosine triphosphate pyrophosphatase (ITPA) gene and RBV induced anemia in a cohort of patients infected with HCV genotype 1 [7] . The identified SNP was found on chromosome 20: rs1127354 (missense variant in exon 2, 94C > A mutation) and rs7270101 (splicing altering SNP in intron 2, IVS2 + 21A > C mutation) [8] . Both rs1127354 and rs7270101 func tional variants are known to cause missplicing of exons 2 and 3 causing the synthesis of protein with reduced enzyme activity [9] and consequently may be associ ated with protective phenotype against RBV induced anemia.
Although CHC is widespread in Ukraine, it has not been spotlighted from the standpoint of host genetic studies. The motivation to conduct this study was to clarify for the first time in CHC Ukrainian patients the association between the variants of the ITPA gene and PEG IFNα and RBV combination treatment induced anemia.
ITPA
MATERIALS AND METHODS The data of this study were collected from 80 Ukrainian CHC patients (43 females, 37 males). All were positive for HCV RNA for more than 6 months and mono infected with chronic hepatitis C with no evidence of HIV or hepatitis B infection. All partici pants were treatment naive patients with no evidence of the presence of any associated liver diseases other than chronic viral hepatitis C. The pretreatment HCV RNA level was detected by quantitative real time poly merase chain reaction (PCR) technique with a lower limit of detection of 300 IU/mL. The high viral load (RNA HCV > 600000 IU/ml) was observed in 46.25% of patients. Qualitative PCR by TaqMan assay was used for detection of viral load at weeks 4, 12, 24 and 48. HCV genotype determination was by sequence deter mination in the 5' nonstructual region of the HCV genome followed by phylogenetic analysis. In all the patients enrolled in this study the HCV genotype 1 infection was detected.
All patients underwent a pretreatment liver biopsy in order to evaluate liver disease activity and fibrosis stage which were scored by the Metavir scoring sys tem. Patients with fibrosis stage of F4 and higher were excluded from the study as they are more prone to cytopenic syndrome regardless of treatment. All study participants received standard doses of the combina tion treatment of PEG IFNα and RBV. In the first week of treatment, all patients were given the fully rec ommended dosages of RBV. During the course of treatment Hb level measurements were performed at least 6-12 times (every 2-4 weeks) for every patient. The steady decrease of Hb level below 130 g/L for men and 120 g/L for women was considered as anemia. According to the Hb level changes all the patients were distributed into two groups: case group-42 patients with combination treatment induced anemia, and control group-38 patients with no signs of anemia. Additionally, a group of 100 unrelated healthy donors from general population of Ukraine (50 females, 50 males) was geno typed for studied polymorphisms. Informed consent was obtained from all participants prior to the collec tion and storage of blood samples for ITPA polymor phism testing. The study has been approved by The Bio ethical Committee of Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine.
The protocol specified a treatment duration of 48 weeks. The majority of patients (55.0%) received PEG IFNα2a (Pegasys) at a dose of 180 μg per week and 45.0% received PEG IFNα2b (Pegintron) as a subcutaneous injection at a dose of 1.5 μg/kg per week. All patients received a 15 mg/kg daily oral dose of RBV (Copegus or Rebetol). However, the study was designed with a futility stopping rule that would halt the trial if there was < 2log10 HCV RNA decline at week 12 or persistent viremia at week 24.
DNA from 80 CHC patients and 100 healthy donors from general population of Ukraine was extracted by standard method using proteinase K with the following chlorophorm extraction. ITPA gene DNA sequence was amplified by routine PCR using mismatched primers to create an XmnI restriction sites as described elsewhere [10] .
Statistical analysis has been performed using GenePop and OpenEpi statistical packages [11, 12] . Fisher's exact test was used to estimate the difference in genotype and allelic distribution. A P value of less than 0.05 was regarded as significant.
RESULTS
The genotype and allele distributions for rs1127354 and rs7270101 variants are presented in the Table 1 . Genotype distribution for both studied polymor phisms in three studied groups was according to Hardy Weinberg equilibrium. Comparative analysis of previously reported rs1127354 and rs7270101 variant minor allele population frequencies [13] and results obtained in this study is shown in Table 2 .
There were no differences found in rs7270101 vari ant allele distribution reported for super populations, which are part of 1000 Genomes project [13] and the ones revealed in this study. On the other hand, rs1127354 variant allele distribution in Ukrainian pop ulation was significantly different compared to African and Ad Mixed American populations.
Genotype and allele distributions of rs1127354 and rs7270101 did not differ between population group and groups of patients with or without anemia. Distri bution of rs7270101 genotypes was not significantly different between groups of CHC patients with RBV induced anemia and without it. The significant differ ence was observed in rs1127354 allele and genotype distributions between studied groups of patients. The rs1127354 A allele carriers frequency was significantly higher (p = 0.04) in group of CHC patients without anemia (23.7%) comparing to the group of patients with anemia (7.3%). The respective allele frequency in group of CHC patients without anemia (13.2%) was more than twofold higher comparing to the case group (4.9%).
DISCUSSION
To our knowledge, this is the first study to assess the impact of the rs1127354 and rs7270101 ITPA geno types on the RBV induced anemia development in Ukrainian patients with chronic hepatitis C infection, regardless of the outcome of treatment. Several previ ous studies have also demonstrated the protective ben efit of the rs1127354 allele A against RBV induced Vol. 49 No. 2 2015 anemia during the first 12 weeks of treatment [14, 15] .The protective impact of ITPA deficiency is sup posed to be as follows. RBV induced anemia mecha nism includes an oxidative damage to erythrocyte membranes and extravascular erythrophagocytosis provoked by accumulation of the RBV metabolitetriphosphorylated RBV [16] . ITPA deficiency causes a strong accumulation of inosine triphosphate (ITP) which competes with triphosphorylated RBV in eryth rocytes and protects cells from the hemolytic effects [17] . Anemia is reported to be a major cause of RBV dose reduction, which in 10-14% of HCV infected patients extends to early withdrawal from treatment in the first 12 weeks [5] . Taking into the account our results as well as results obtained in other studies, RBV dose reduction in the early weeks of treatment is evi dently necessary for patients with rs1127354 CC.
In conclusion, the significant association of ITPA gene rs1127354 with protection against RBV induced hemolytic anemia has been found in Ukrainian patients with chronic hepatitis C infection. ITPA genotyping, may assist in HCV antiviral therapy cor rection in patients, particularly ones at high risk for hemolytic anemia or anemia related morbidity.
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